SCHEMBL6135040

SCHEMBL6135040

COC(=O)c1ccc(C(=O)NNC(=O)c2ccc(N3CCN(C4CCC5(CC4)OCC(C)(C)CO5)CC3)cc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.43
RAB9A P51151 2/20 0.43
NPC1 O15118 1/20 0.43
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
ALDH1A1 P00352 7/20 0.41
KDM4E B2RXH2 4/20 0.40
TDP1 Q9NUW8 1/20 0.40
MAPT P10636 4/20 0.39
HDAC3 O15379 5/20 0.39
HDAC8 Q9BY41 5/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
HSP90AA1 P07900 1/20 0.38
MBTD1 Q05BQ5 1/20 0.38
TP53BP1 Q12888 1/20 0.38
L3MBTL4 Q8NA19 1/20 0.38
L3MBTL3 Q96JM7 1/20 0.38
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6134440 0.91 KMT2A (0.45) SMN1; SMN2RAB9AKMT2AMEN1ALDH1A1
SCHEMBL6135046 0.86 KMT2A (0.46) KMT2AMEN1ALDH1A1KDM4EMAPT
SCHEMBL6135117 0.85 HRH3 (0.42) SMN1; SMN2RAB9ANPC1KMT2AMEN1
SCHEMBL6134698 0.84 ALDH1A1 (0.47) SMN1; SMN2KMT2AMEN1ALDH1A1TDP1
SCHEMBL6134612 0.82 ALDH1A1 (0.49) SMN1; SMN2RAB9ANPC1KMT2AMEN1
SCHEMBL6134989 0.82 ALDH1A1 (0.51) KMT2AMEN1ALDH1A1KDM4ETDP1
SCHEMBL6132317 0.81 ALDH1A1 (0.50) SMN1; SMN2RAB9ANPC1KMT2AMEN1
SCHEMBL6134631 0.81 HDAC3 (0.50) SMN1; SMN2KMT2AMEN1ALDH1A1KDM4E
SCHEMBL6134863 0.80 KMT2A (0.51) RAB9ANPC1KMT2AMEN1ALDH1A1
SCHEMBL6134378 0.78 ALDH1A1 (0.51) SMN1; SMN2KMT2AMEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050261177-A1 Compound ASTELLAS PHARMA INC. (JP) 2005-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261177-A1 Compound MANBA, MAN2B1, MAN2A1 SMN1; SMN2 3682/4885RAB9A 3326/4885NPC1 1070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.